306 related articles for article (PubMed ID: 25542645)
1. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
[TBL] [Abstract][Full Text] [Related]
3. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.
Blanco E; Bey EA; Dong Y; Weinberg BD; Sutton DM; Boothman DA; Gao J
J Control Release; 2007 Oct; 122(3):365-74. PubMed ID: 17574288
[TBL] [Abstract][Full Text] [Related]
4. Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.
Ma X; Huang X; Huang G; Li L; Wang Y; Luo X; Boothman DA; Gao J
Adv Healthc Mater; 2014 Aug; 3(8):1210-6. PubMed ID: 24532286
[TBL] [Abstract][Full Text] [Related]
5. β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Zhang L; Chen Z; Yang K; Liu C; Gao J; Qian F
Mol Pharm; 2015 Nov; 12(11):3999-4010. PubMed ID: 26415823
[TBL] [Abstract][Full Text] [Related]
6. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
Blanco E; Bey EA; Khemtong C; Yang SG; Setti-Guthi J; Chen H; Kessinger CW; Carnevale KA; Bornmann WG; Boothman DA; Gao J
Cancer Res; 2010 May; 70(10):3896-904. PubMed ID: 20460521
[TBL] [Abstract][Full Text] [Related]
7. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
8. Oligo(Lactic Acid)
Tam YT; Repp L; Ma ZX; Feltenberger JB; Kwon GS
Pharm Res; 2019 Mar; 36(5):70. PubMed ID: 30888509
[TBL] [Abstract][Full Text] [Related]
9. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
10. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
[TBL] [Abstract][Full Text] [Related]
11. Stereocomplex Prodrugs of Oligo(lactic acid)
Tam YT; Huang C; Poellmann M; Kwon GS
ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
[TBL] [Abstract][Full Text] [Related]
12. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
13. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
[TBL] [Abstract][Full Text] [Related]
14. A Carbon-Carbon Bond Cleavage-Based Prodrug Activation Strategy Applied to β-Lapachone for Cancer-Specific Targeting.
Gong Q; Li X; Li T; Wu X; Hu J; Yang F; Zhang X
Angew Chem Int Ed Engl; 2022 Oct; 61(40):e202210001. PubMed ID: 35938884
[TBL] [Abstract][Full Text] [Related]
15. Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)
Tam YT; Shin DH; Chen KE; Kwon GS
J Control Release; 2019 Mar; 298():186-193. PubMed ID: 30790593
[TBL] [Abstract][Full Text] [Related]
16. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis.
Wu Y; Wang X; Chang S; Lu W; Liu M; Pang X
J Pharmacol Exp Ther; 2016 Jun; 357(3):466-75. PubMed ID: 27048660
[TBL] [Abstract][Full Text] [Related]
17. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.
Choi EK; Terai K; Ji IM; Kook YH; Park KH; Oh ET; Griffin RJ; Lim BU; Kim JS; Lee DS; Boothman DA; Loren M; Song CW; Park HJ
Neoplasia; 2007 Aug; 9(8):634-42. PubMed ID: 17786182
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock.
Song CW; Chae JJ; Choi EK; Hwang TS; Kim C; Lim BU; Park HJ
Int J Hyperthermia; 2008 Mar; 24(2):161-9. PubMed ID: 18283592
[TBL] [Abstract][Full Text] [Related]
20. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
